Idorsia Pharmaceuticals Ltd

Hegenheimermattweg 91, Allschwil, Basel-Land, Switzerland

Clinical Trials

112

100 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

101

90.2%

Phase 3

2.7%

Trial Status Distribution

Active, not recruiting

88.4%

Completed

8.0%

Not yet recruiting

0.9%

Recruiting

2.7%

Clinical Trials

Trials sponsored by this organization (112)

Selatogrel Outcome Study in Suspected Acute Myocardial Infarction (SOS-AMI)

Phase 3

Not yet recruiting

interventional

Jun 202514,000 participants

A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus (OPUS-2)

Phase 3

Recruiting

interventional

Nov 20238 participants

Selatogrel Outcome Study in Suspected Acute Myocardial Infarctio

Phase 1

Active, not recruiting

interventional

Feb 202314,000 participants

A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from Systemic Lupus Erythematosus

Phase 1

Recruiting

interventional

Dec 2022420 participants

Selatogrel Outcome Study in Suspected Acute Myocardial Infarctio

Phase 1

Active, not recruiting

interventional

Dec 202214,000 participants

Phase I trial: Fortrea Clinical Pharmacology Services 1006539

Phase 1

Active, not recruiting

interventional

Dec 2022106 participants

A study to find out which dose of daridorexant is safe and effective to treat insomnia in children and adolescents 10 to <18 years old

Phase 1

Active, not recruiting

Dec 2022150 participants

A research study to evaluate the efficacy and safety of cenerimod in subjects suffering from Systemic Lupus Erythematosus

Phase 1

Recruiting

interventional

Nov 2022420 participants

Page 1 of 14

Approvals

Approvals by Agency

FDA

Food and Drug Administration

Approvals

CANADA

Health Canada

Approvals

Recent Approvals

News

No news articles found

Back to Organizations